[Pubmed] Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis pa
Posté : 21 août 2024 12:00
iScience. 2024 Jul 23;27(8):110564. doi: 10.1016/j.isci.2024.110564. eCollection 2024 Aug 16.
ABSTRACT
There is an unmet need for objective disease-specific biomarkers in the heterogeneous autoimmune neuromuscular disorder myasthenia gravis (MG). This cross-sectional study identified a signature of 23 inflammatory serum proteins with proximity extension assay (PEA) that distinguishes acetylcholine receptor antibody seropositive (AChR+) MG patients from healthy controls (HCs). CCL28, TNFSF14, 4E-BP1, transforming growth factor alpha (TGF-α), and ST1A1 ranked top biomarkers. TGF-β1 and osteoprotegerin (OPG) differed between early- and late-onset MG, whereas CXCL10, TNFSF14, CCL11, interleukin-17C (IL-17C), and TGF-α differed significantly with immunosuppressive treatment. MG patients with moderate to high disease severity had lower uPA. Previously defined MG-associated microRNAs, miR-150-5p, miR-30e-5p, and miR-21-5p, correlated inversely with ST1A1 and TNFSF14. The presented inflammatory proteins that distinguish AChR+ MG are promising serum biomarkers for validation in prospective studies to allow for molecular signatures for patient subgroup stratification and monitoring of treatment response.
PMID:39165841 | PMC:PMC11334828 | DOI:10.1016/j.isci.2024.110564
Source: https://pubmed.ncbi.nlm.nih.gov/3916584 ... t9+e462414